Abbott (ABT) announced the U.S. FDA has approved the company’s Volt PFA System to treat patients battling atrial fibrillation. Abbott will soon begin commercial PFA cases in the United States and will continue its expansion of sites in the European Union following Volt CE Mark approval earlier this year.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott’s Amplatzer Piccolo Delivery System granted FDA and CE clearance
- Abbott Laboratories Expands Board with New Appointment
- Abbott increases quarterly dividend by 6.8% to 63c per share
- 3 Best ETFs to Invest In, According to AI Analyst, 12/09/2025
- Abbott says Lingo CGM now available on Android devices